Results 21 to 30 of about 291,495 (261)

Review of global use of licensed vaccines and development of new vaccines for the prevention of pneumococcal infection

Биопрепараты: Профилактика, диагностика, лечение, 2021
Streptococcus pneumoniae infection is the most common cause of high morbidity and mortality among children under 5 years of age, immunocompromised people, and the elderly.
M. V. Savkina, M. A. Krivykh, N. A. Gavrilova, L. V. Sayapina, Yu. I. Obukhov, V. A. Merkulov, V. P. Bondarev   +6 more
doaj   +1 more source

Vaccine Technologies and Platforms for Infectious Diseases: Current Progress, Challenges, and Opportunities

Vaccines, 2021
Vaccination is a key component of public health policy with demonstrated cost-effective benefits in protecting both human and animal populations. Vaccines can be manufactured under multiple forms including, inactivated (killed), toxoid, live attenuated ...
Majed Ghattas, Garima Dwivedi, Marc Lavertu, Mohamad-Gabriel Alameh   +3 more
doaj   +1 more source

Promising pharmaceutical development of vaccines for the prevention of meningococcal infection

Журнал микробиологии, эпидемиологии и иммунобиологии, 2023
Meningococcal infection (MI) refers to anthroponoses; is an acute infectious disease with an aerosol transmission mechanism, characterized by various forms of the infectious process: from local (nasopharyngitis) and asymptomatic infections to generalized
Maria V. Savkina, Lidiya V. Sayapina, Maxim A. Krivykh, Yury I. Obukhov   +3 more
doaj   +1 more source

Promising directions for vaccine development to prevent shigellosis

Биопрепараты: Профилактика, диагностика, лечение, 2022
Shigellosis (bacterial dysentery) is an acute infectious disease caused by Shigella spp., members of the Enterobacteriaceae family. The disease has the highest mortality rate amongst bacterial enteric infections.
M. V. Abramtseva, E. O. Nemanova, N. S. Alekhina   +2 more
doaj   +1 more source

The impact and effectiveness of pneumococcal vaccination in Scotland for those aged 65 and over during winter 2003/2004 [PDF]

, 2008
Background: For winter 2003/2004 in Scotland, it was recommended that all those aged 65 and over be eligible to receive 23-valent polysaccharide pneumococcal vaccine (23vPPV), which has been shown to be effective in reducing the risk of invasive ...
Simpson, Colin R, Ahmed, S., Macfarlane, Tatania V., McMenamin, J., Weir, Amanda, Lewis D Ritchie, Mooney John D, McMenamin, Jim, Robertson, C., Weir, A.M., Jim McMenamin, Macfarlane, Tatania V, Ritchie Lewis D, Clarke, Stuart C., Clarke Stuart C, Simpson, Colin R., Mooney, John D., Robertson Chris, Tatania V Macfarlane, Amanda Weir, Syed Ahmed, Mooney, John D, Stuart C Clarke, Simpson, C.R., Chris Robertson, Ritchie, L.D., Mooney, J.D., Ahmed, Syed, Macfarlane Tatania V, Ritchie, Lewis D, McMenamin Jim, Weir Amanda, Clarke, Stuart C, Colin R Simpson, Clarke, S.C., Ahmed Syed, Robertson, Chris, Macfarlane, T.V., Ritchie, Lewis D., Simpson Colin R, John D Mooney   +40 more
core   +5 more sources

Adjuvants : an essential component of neisseria vaccines [PDF]

, 2009
Adjuvants may be classified into delivery systems and immune potentiator or modulator molecules based on their mechanism of action. Neisseria vaccines containing traditional adjuvants such as aluminium salts have existed for long time, but meningitis ...
Acevedo, R., del Campo, J., Zayas, C., Cuello, M., Romeu, B., Ferro, Valerie A., Gonzales, E., Cabrera, O., Balbao, J.   +8 more
core   +4 more sources

Non-capsular based immunization approaches to prevent Streptococcus pneumoniae infection

Frontiers in Cellular and Infection Microbiology, 2022
Streptococcus pneumoniae is a Gram-positive bacterium and the leading cause of bacterial pneumonia in children and the elderly worldwide. Currently, two types of licensed vaccines are available to prevent the disease caused by this pathogen: the 23 ...
Pedro H. Silva, Pedro H. Silva, Yaneisi Vázquez, Yaneisi Vázquez, Camilo Campusano, Camilo Campusano, Angello Retamal-Díaz, Margarita K. Lay, Christian A. Muñoz, Pablo A. González, Pablo A. González, Alexis M. Kalergis, Alexis M. Kalergis, Susan M. Bueno, Susan M. Bueno   +14 more
doaj   +1 more source

A glycoconjugate of Haemophilus influenzae Type b capsular polysaccharide with tetanus toxoid protein: hydrodynamic properties mainly influenced by the carbohydrate [PDF]

, 2016
Three important physical properties which may affect the performance of glycoconjugate vaccines against serious disease are molar mass (molecular weight), heterogeneity (polydispersity), and conformational flexibility in solution.
Harding, Stephen E., Conrath, K., Almuntari, F., Almutairi, Fahad M., Duvivier, Pierre, Harding, S. E., Adams, G. G., Morris, Gordon, Duvivier, P., Morris, Gordon A., Abdelhameed, Ali Saber, Adams, Gary G., Abdelhameed, A. S., Conrath, Karel, GSK Vaccines, Rue de l’Institut 89, B-1330 Rixensart, Belgium   +14 more
core   +1 more source

Heterologous expression of the pneumococcal serotype 14 polysaccharide in Lactococcus lactis requires lactococcal epsABC regulatory genes [PDF]

, 2008
The pneumococcal serotype 14 polysaccharide was produced in Lactococcus lactis by coexpressing pneumococcal polysaccharide type 14-specific genes (cpsFGHIJKL(14)) with the lactococcal regulatory and priming glucosyltransferase-encoding genes specific for
Kleerebezem, M., Masja N. Nierop Groot, Michiel Kleerebezem, Jeroen Godefrooij, Nierop Groot, M.N., Godefrooij, J.   +5 more
core   +1 more source

Reduction of free polysaccharide contamination in the production of a 15-valent pneumococcal conjugate vaccine.

PLoS ONE, 2020
Glycoconjugate vaccines are vaccines in which a bacterial polysaccharide antigen is conjugated to a carrier protein to enhance immunogenicity by promoting T cell-dependent immune response. However, the free (unreacted) polysaccharides remaining after the
Yoon Hee Whang, Soo Kyung Kim, Hyeseon Yoon, Seuk Keun Choi, Yeong Ok Baik, Chankyu Lee, Inhwan Lee   +6 more
doaj   +1 more source